Complement levels in septic primates treated with anti-C5a antibodies
- PMID: 2493531
- DOI: 10.1016/0022-4804(89)90055-3
Complement levels in septic primates treated with anti-C5a antibodies
Abstract
During gram-negative sepsis it is known that endotoxin activates complement by the alternate pathway. The complement anaphylatoxin C5a, a result of this activation, is thought to play a key role in attracting and activating neutrophils in the lungs, leading to the adult respiratory distress syndrome. Complement levels were measured in primates made septic by Escherichia coli infusions. Anti-human C5a antibodies were administered to study their effect on neutrophil-mediated lung injury. Control (I), septic (II) and septic + anti-C5a antibody (III) groups (n = 4) were studied. The antibody-treated group (III) demonstrated a significant attenuation of septic shock and pulmonary edema as has been previously reported. All complement profiles were corrected for varying hemoglobin concentrations. C3, C4, and C5 levels were measured by radial immunodiffusion and were depleted in both septic groups. Once the levels were depleted from the plasma, they did not recover. The depletion of C4 indicates that classical pathway activation also occurred. C3a, C4a, and C5a levels were measured by radioimmunoassay. Significantly increased peak levels were reached in the septic groups 15 min after initiation of the E. coli infusion. There were no significant differences in early peak C3a and C4a levels between groups II and III. However, the mean peak C5a level in group III (anti-C5a antibodies) was 42% lower than that in group II, and after this early peak, C5a levels were not elevated above control levels in group III. The antibody to human C5a was thus shown to be cross-reactive with primate C5a and was specific since C3a and C4a levels were not decreased in group III.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates.J Clin Invest. 1986 Jun;77(6):1812-6. doi: 10.1172/JCI112506. J Clin Invest. 1986. PMID: 3711336 Free PMC article.
-
Biologically active products of complement and acute lung injury in patients with the sepsis syndrome.Am Rev Respir Dis. 1984 Nov;130(5):791-6. doi: 10.1164/arrd.1984.130.5.791. Am Rev Respir Dis. 1984. PMID: 6497161
-
Complement activation in type 1 human diabetes.Clin Immunol Immunopathol. 1985 May;35(2):211-25. doi: 10.1016/0090-1229(85)90067-4. Clin Immunol Immunopathol. 1985. PMID: 3907907
-
[Complement activation and inflammation].Rinsho Byori. 2006 Jul;54(7):744-56. Rinsho Byori. 2006. PMID: 16913666 Review. Japanese.
-
C5 neoepitopes appearing during activation.Complement Inflamm. 1989;6(3):219-22. doi: 10.1159/000463095. Complement Inflamm. 1989. PMID: 2472923 Review.
Cited by
-
The complement cascade in lung injury and disease.Respir Res. 2024 Jan 4;25(1):20. doi: 10.1186/s12931-023-02657-2. Respir Res. 2024. PMID: 38178176 Free PMC article. Review.
-
Complement as driver of systemic inflammation and organ failure in trauma, burn, and sepsis.Semin Immunopathol. 2021 Dec;43(6):773-788. doi: 10.1007/s00281-021-00872-x. Epub 2021 Jun 30. Semin Immunopathol. 2021. PMID: 34191093 Free PMC article. Review.
-
Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC).Clin Exp Immunol. 1993 Feb;91(2):295-300. doi: 10.1111/j.1365-2249.1993.tb05898.x. Clin Exp Immunol. 1993. PMID: 7679061 Free PMC article.
-
The role of complement system in septic shock.Clin Dev Immunol. 2012;2012:407324. doi: 10.1155/2012/407324. Epub 2012 Sep 23. Clin Dev Immunol. 2012. PMID: 23049598 Free PMC article. Review.
-
The harmful role of c5a on innate immunity in sepsis.J Innate Immun. 2010;2(5):439-45. doi: 10.1159/000317194. Epub 2010 Jun 26. J Innate Immun. 2010. PMID: 20588003 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous